#1 Clinical Trials Search in Europe

Cyclophosphamide Monohydrate

Cyclophosphamide Monohydrate is a chemotherapy drug being studied in various clinical trials for treating different types of cancer. This article explores how this medication is being used in combination with other therapies to potentially improve outcomes for patients with conditions like lymphoma, breast cancer, and other advanced cancers. We’ll look at some key trials examining its effectiveness, safety, and optimal dosing strategies.

Table of Contents

What is Cyclophosphamide?

Cyclophosphamide is a powerful medication used in the treatment of various cancers and autoimmune disorders. It belongs to a class of drugs known as alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from dividing and growing[1]. Cyclophosphamide is also known by other names, including Cytoxan and Endoxan[2][3].

Conditions Treated with Cyclophosphamide

Cyclophosphamide is used to treat a variety of conditions, including:

  • Multiple Myeloma: A type of blood cancer that affects plasma cells[4][3]
  • Breast Cancer: Particularly in early-stage and metastatic forms[5][6]
  • Colorectal Cancer: Especially in metastatic cases[2]
  • Non-Small Cell Lung Cancer[7]
  • Sarcomas: Including synovial sarcoma and soft tissue sarcomas[7]
  • Melanoma: Particularly stage IV[7]
  • Bladder Urothelial Carcinoma[7]
  • Neuroblastoma: A type of cancer that develops from immature nerve cells[7]

How Cyclophosphamide Works

Cyclophosphamide is a type of chemotherapy drug that works by damaging the DNA of rapidly dividing cells, such as cancer cells. This damage prevents the cells from reproducing and ultimately leads to their death. While it primarily targets cancer cells, it can also affect other fast-growing cells in the body, which is why it may cause side effects[1].

How Cyclophosphamide is Administered

Cyclophosphamide can be administered in several ways, depending on the specific treatment plan:

  • Oral tablets: Taken daily at a low dose in some regimens[2]
  • Intravenous (IV) infusion: Given through a vein, often as part of a combination therapy[1]
  • Different dosing schedules: Can be given in high doses less frequently or in lower doses more frequently (known as metronomic dosing)[6]

The specific dosage and schedule will depend on the condition being treated, the patient’s overall health, and other factors determined by the healthcare team.

Combination Therapies

Cyclophosphamide is often used in combination with other medications to enhance its effectiveness. Some common combination therapies include:

  • FEC regimen: Fluorouracil, Epirubicin, and Cyclophosphamide, used in breast cancer treatment[5]
  • FOLFOXIRI plus Bevacizumab: A combination used in colorectal cancer treatment that includes cyclophosphamide[1]
  • Cyclophosphamide with Bortezomib (Velcade) and G-CSF: Used in multiple myeloma treatment[3]
  • Metronomic chemotherapy: Low-dose cyclophosphamide combined with other drugs like capecitabine, methotrexate, and celecoxib[2]

Potential Side Effects

Like all medications, cyclophosphamide can cause side effects. Some potential side effects include:

  • Hematologic toxicities: Such as low white blood cell count (neutropenia) or low platelet count (thrombocytopenia)[4]
  • Nausea and vomiting[8]
  • Hair loss (alopecia)[8]
  • Fatigue
  • Increased risk of infections due to lowered immune function

Your healthcare team will monitor you closely for these side effects and may adjust your treatment as needed.

Ongoing Research and Clinical Trials

Researchers continue to study cyclophosphamide to find new ways to use it effectively and safely. Some areas of ongoing research include:

  • Metronomic chemotherapy: Using low, frequent doses of cyclophosphamide to potentially reduce side effects and improve efficacy[2]
  • Combination therapies: Testing cyclophosphamide with newer drugs or in different combinations to improve treatment outcomes[7]
  • Stem cell mobilization: Using cyclophosphamide to help collect stem cells for transplantation in multiple myeloma patients[3]
  • Neoadjuvant therapy: Using cyclophosphamide before surgery in breast cancer patients to potentially improve outcomes[6]

These ongoing studies aim to optimize the use of cyclophosphamide and improve patient outcomes across various cancer types.

Trial Focus Cancer Type Combination Therapy Key Outcomes Measured
CAR-T cell therapy Large B-cell Lymphoma Fludarabine, Axicabtagene Ciloleucel Safety, efficacy, cytokine release syndrome
Immunotherapy combination Metastatic Renal Cell Carcinoma Pembrolizumab Objective response rate, progression-free survival
Low-dose metronomic Metastatic Breast Cancer Veliparib Recommended phase II dose, clinical benefit
Older patient focus Multiple Myeloma MUC1-activated T-cells Safety, feasibility, immune response
Dose reduction study Early-stage Breast Cancer Docetaxel Relative dose intensity, treatment tolerability

FAQ

  • What types of cancer is Cyclophosphamide Monohydrate being studied for? Cyclophosphamide Monohydrate is being studied in clinical trials for various cancers including lymphoma, breast cancer, renal cell carcinoma, gastric cancer, and prostate cancer. It's often used in combination with other treatments like immunotherapies or targeted therapies.
  • How is Cyclophosphamide Monohydrate typically administered? Cyclophosphamide Monohydrate is usually given intravenously (through an IV) or orally as a pill. The dosing and schedule can vary depending on the specific trial and treatment regimen. Some trials are exploring lower dose 'metronomic' dosing given more frequently.
  • What are some potential side effects of Cyclophosphamide Monohydrate? Common side effects can include nausea, hair loss, fatigue, and increased risk of infections. More serious side effects may include bladder problems, fertility issues, and secondary cancers. Side effects are closely monitored in clinical trials.
  • Why is Cyclophosphamide Monohydrate often combined with other drugs in trials? Combining Cyclophosphamide Monohydrate with other treatments may improve effectiveness against cancer. For example, it's being studied with immunotherapies to potentially enhance the immune response against tumors.
  • Are there any trials looking at Cyclophosphamide Monohydrate for older or more vulnerable patients? Yes, some trials are exploring lower doses or alternative schedules of Cyclophosphamide Monohydrate for older or more vulnerable patients to reduce side effects while maintaining effectiveness. This includes studies in breast cancer and multiple myeloma.

Ongoing Clinical Trials on Cyclophosphamide Monohydrate

  • Study on Pembrolizumab and Cyclophosphamide for Patients with Metastatic Urothelial Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on the Safety and Effectiveness of Sargramostim with Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone in Untreated Light Chain Amyloidosis Patients

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Poland

  • Study on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Isatuximab with drug combination for newly diagnosed multiple myeloma patients with severe kidney problems

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Greece

  • Study of Pembrolizumab and Cyclophosphamide for Patients with Inflammatory Breast Cancer on the Chest Wall

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study Comparing Venetoclax and Obinutuzumab with Drug Combination for Fit Patients with Untreated Chronic Lymphocytic Leukemia Without Specific Genetic Mutations

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France Italy Spain

  • Study of Rapcabtagene Autoleucel and Ibrutinib for Adults with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Other Blood Cancers

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria France Germany Italy Spain

  • Study of Palbociclib with Drug Combinations for Children and Young Adults with Recurrent or Refractory Neuroblastoma and Ewing Sarcoma

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Czechia France Germany Slovakia Sweden

  • Study on Reducing Side Effects in Advanced Hodgkin Lymphoma Using Brentuximab Vedotin and Drug Combination for Newly Diagnosed Patients

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Denmark Germany The Netherlands Norway Sweden

  • Study on the Effectiveness and Safety of Cyclophosphamide Monohydrate and Drug Combination for Patients with Persistent or Recurrent Rare Epithelial Ovarian Tumors

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Italy Spain

Glossary

  • Cyclophosphamide Monohydrate: A chemotherapy drug used to treat various types of cancer. It works by damaging the DNA of cancer cells, preventing them from dividing and growing.
  • Metastatic: Cancer that has spread from where it started to other parts of the body.
  • Refractory: A disease that does not respond to treatment.
  • Immunotherapy: A type of cancer treatment that helps your immune system fight cancer.
  • CAR-T therapy: A type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells.
  • Cytokine release syndrome: A condition that may occur after some types of immunotherapy, causing symptoms like fever, nausea, and headache.
  • Metronomic dosing: A method of giving low doses of chemotherapy drugs on a frequent or continuous schedule.
  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall survival: The length of time from the start of treatment that patients are still alive.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment.

References

  1. https://clinicaltrials.gov/study/NCT02271464
  2. https://clinicaltrials.gov/study/NCT02280694
  3. https://clinicaltrials.gov/study/NCT01146834
  4. https://clinicaltrials.gov/study/NCT01346787
  5. https://clinicaltrials.gov/study/NCT00055679
  6. https://clinicaltrials.gov/study/NCT00542191
  7. https://clinicaltrials.gov/study/NCT05296564
  8. https://clinicaltrials.gov/study/NCT02225652